Vonk Lucienne A, de Windt Tommy S, Slaper-Cortenbach Ineke C M, Saris Daniël B F
Department of Orthopaedics, University Medical Center Utrecht, HP G05.228, PO Box 85090, 3508 GA, Utrecht, The Netherlands.
Cell Therapy Facility, Department of Clinical Pharmacy, University Medical Center Utrecht, HP F03.821, PO Box 85090, 3508 GA, Utrecht, The Netherlands.
Stem Cell Res Ther. 2015 May 15;6(1):94. doi: 10.1186/s13287-015-0086-1.
The evolution of articular cartilage repair procedures has resulted in a variety of cell-based therapies that use both autologous and allogeneic mesenchymal stromal cells (MSCs). As these cells are increasingly available and show promising results both in vitro and in vivo, cell-based strategies, which aim to improve ease of use and cost-effectiveness, are progressively explored. The use of MSCs in cartilage repair makes it possible to develop single-stage cell-based therapies. However, true single-stage procedures rely on one intervention, which will limit cell sources to fraction concentrates containing autologous MSCs or culture-expanded allogeneic MSCs. So far, it seems both autologous and allogeneic cells can safely be applied, but clinical studies are still ongoing and little information on clinical outcome is available. Further development of cell-based therapies may lead to clinical-grade, standardized, off-the-shelf products with easy handling for orthopedic surgeons. Although as of yet no preclinical or clinical studies are ongoing which explore the use of induced pluripotent stem cells for cartilage repair, a good manufacturing practice-grade induced pluripotent stem cell line might become the basis for such a product in the future, providing that cell fate can be controlled. The use of stem cells in clinical trials brings along new ethical issues, such as proper controls and selecting primary outcome measures. More clinical trials are needed to estimate detailed risk-benefit ratios and trials must be carefully designed to minimize risks and burdens for patients while choosing outcome measures that allow for adequate comparison with results from similar trials. In this review, we discuss the different aspects of new stem cell-based treatments, including safety and ethical issues, as well as provide an overview of current clinical trials exploring these approaches and future perspectives.
关节软骨修复手术的发展催生了多种基于细胞的疗法,这些疗法使用自体和异体间充质基质细胞(MSC)。随着这些细胞越来越容易获得,并且在体外和体内都显示出有前景的结果,旨在提高易用性和成本效益的基于细胞的策略也在逐步探索。在软骨修复中使用MSC使得开发单阶段基于细胞的疗法成为可能。然而,真正的单阶段手术依赖于一次干预,这将把细胞来源限制为含有自体MSC的分数浓缩物或培养扩增的异体MSC。到目前为止,自体和异体细胞似乎都可以安全应用,但临床研究仍在进行中,关于临床结果的信息很少。基于细胞的疗法的进一步发展可能会产生临床级、标准化、现成的产品,便于骨科医生操作。尽管目前尚无探索诱导多能干细胞用于软骨修复的临床前或临床研究,但如果能够控制细胞命运,一个符合良好生产规范的诱导多能干细胞系可能会成为未来这类产品的基础。在临床试验中使用干细胞带来了新的伦理问题,如适当的对照和选择主要结局指标。需要更多的临床试验来评估详细的风险效益比,并且试验必须精心设计,以尽量减少患者的风险和负担,同时选择能够与类似试验结果进行充分比较的结局指标。在这篇综述中,我们讨论了基于干细胞的新疗法的不同方面,包括安全性和伦理问题,并概述了目前探索这些方法的临床试验及未来前景。